COMPENSATION OF NAMED EXECUTIVE OFFICERS
EX-10.35 5 dex1035.htm SUMMARY OF COMPENSATION ARRANGEMENTS Summary of compensation arrangements
Exhibit 10.35
COMPENSATION OF NAMED EXECUTIVE OFFICERS
| Name and Position | Fiscal 2009 Base Salary ($) | Fiscal 2009 Bonus ($) | Fiscal 2010 Base Salary ($) | |||
| Peter D. Meldrum President and Chief Executive Officer | 800,000 | 1,000,000 | 832,000 | |||
| Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | 550,000 | 415,000 | 565,000 | |||
| Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. (1) | 535,000 | 285,000 | N/A | |||
| James S. Evans Chief Financial Officer | 375,000 | 265,000 | 400,000 | |||
| Mark H. Skolnick, Ph.D. (2) Chief Scientific Officer | 520,000 | 135,000 | 530,000 | |||
| Richard Marsh Executive Vice-President, General Counsel and Secretary | 360,000 | 210,000 | 385,000 | |||
| (1) | As part of the separation of MPI on June 30, 2009, Dr. Hobden ceased his employment with Myriad Genetics and transferred to the new company as Chief Executive Officer, effective June 30, 2009 |
| (2) | Dr. Skolnick is compensated on an hourly basis. Base salary information reflects an annualized salary based on 2080 hours worked in a fiscal year. Actual amounts paid to Dr. Skolnick may vary significantly depending on the actual number of hours worked. |
